Bringing the fundamentals into focus…
Back to Enanta Pharmaceuticals, Inc.
How Enanta Pharmaceuticals, Inc. stacks up
ENTA · against 317 other Healthcare companies of similar size
Growth
31/ 100
Below the middle of the pack.
Ranked #186 of 318 · scores higher than 40% of peers
Bars: peers in each 10-point band of the growth score35 peers with a growth score of 30–39, including ENTA · Click a bar to see the companies
Why growth scores 31?
Weighted metrics compared with all Healthcare companies.Mainly because of its 3-year revenue growth and revenue growth, which are weaker than most Healthcare peers.
- slower revenue growth over three years: weaker than 84% of peers. 3-year revenue growth: -6.8% vs peer median 5.8%
- slower revenue growth over the last year: weaker than 68% of peers. Revenue growth: 0.7% vs peer median 6.1%
- Still loss-making, but the loss per share narrowed. Earnings per share growth: — vs peer median 9.8%
Metric by metric
Position: dot = ENTA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ENTA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 330 reported | 0.7% | 3.0% | 43% | 33% | |
| Earnings per share growthHigher is better · 145 reported | Not reported | 2.2% | — | — | 33% |
| 3-year revenue growthHigher is better · 309 reported | -6.8% | 3.7% | 24% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around ENTA| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 464M USD | 100 | 53 | |
| 2 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 2 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 2 | 592M ILS (≈$160M) | 99 | 84 | |
| 2 | 433M USD | 99 | 81 | |
| 186 | 1.6B CNY (≈$223M) | 31 | 46 | |
| 186 | 2.2B CNY (≈$310M) | 31 | 39 | |
| 186 | 63.5B JPY (≈$432M) | 31 | 57 | |
| 186 | 493M USD | 31 | 38 | |
| 186 | 302M USD | 31 | 17 | |
| 192 | 3.8B HKD (≈$486M) | 30 | 56 | |
| 192 | 3.3B CNY (≈$463M) | 30 | 26 | |
| 192 | 3.6B CNY (≈$507M) | 30 | 29 | |
| 192 | 486M USD | 30 | 16 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score